Teriflunomide

Neurology: Clinical Practice

Volumn 3, Issue 3, 2013, Pages 254-260

  Oh, Jiwon ^a,b   O'Connor, Paul W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; ETHINYLESTRADIOL; FUMARIC ACID DIMETHYL ESTER; LEFLUNOMIDE; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PIOGLITAZONE; PLACEBO; REPAGLINIDE; TERIFLUNOMIDE; THEOPHYLLINE; TIZANIDINE; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOOD INTAKE; HEADACHE; HUMAN; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; RESPIRATORY TRACT INFECTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SUICIDE;

EID: 84880304291     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e318296f299     Document Type: Article

References (14)

1. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-1049.
2. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270:12398-12403.
3. Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005;52:2730-2739.
4. Limsakun T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Neurology 2010;74:A415.
5. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New Engl J Med 2011;365:1293-1303.
6. Kappos L. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study. In: ECTRIMS. Lyon, France; 2012.
7. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology 2012;78:1877-1885.
8. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012; 18:1278-1289.
9. White DH, Lynskey NV, Jones PB. Leflunomide use in New Zealand. A national prospective postmarketing study. Intern Med J 2009;39:95-102.
10. Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003; 62:50-57.
11. Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008;65:1538-1539.
12. Kieseier B. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. In: ECTRIMS. Lyon, France; 2012.
13. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900.
14. Vermersch P. A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. In: ECTRIMS. Lyon, France; 2012.